Zacks Research Analysts Boost Earnings Estimates for COO

The Cooper Companies, Inc. (NASDAQ:COO) – Investment analysts at Zacks Research increased their Q3 2027 earnings estimates for shares of Cooper Companies in a research report issued to clients and investors on Thursday, March 26th. Zacks Research analyst Team now expects that the medical device company will post earnings of $1.25 per share for the quarter, up from their previous estimate of $1.24. The consensus estimate for Cooper Companies’ current full-year earnings is $3.98 per share.

Cooper Companies (NASDAQ:COO) last posted its earnings results on Thursday, March 5th. The medical device company reported $1.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.03 by $0.07. The company had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.02 billion. Cooper Companies had a return on equity of 10.34% and a net margin of 9.67%.The firm’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same quarter last year, the firm earned $0.92 earnings per share. Cooper Companies has set its Q2 2026 guidance at 4.580-4.660 EPS.

COO has been the topic of several other reports. KeyCorp reiterated a “sector weight” rating on shares of Cooper Companies in a research note on Friday, December 5th. Wells Fargo & Company upped their price target on Cooper Companies from $72.00 to $82.00 and gave the stock an “equal weight” rating in a report on Friday, December 5th. Mizuho set a $100.00 price target on Cooper Companies and gave the company an “outperform” rating in a research report on Friday, December 5th. William Blair upgraded Cooper Companies to a “strong-buy” rating in a research note on Friday, January 30th. Finally, Needham & Company LLC boosted their price objective on Cooper Companies from $99.00 to $101.00 and gave the stock a “buy” rating in a research report on Friday, March 6th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Cooper Companies presently has an average rating of “Moderate Buy” and an average price target of $90.79.

Cooper Companies Price Performance

Shares of COO opened at $69.77 on Monday. The company’s 50-day simple moving average is $78.82 and its 200-day simple moving average is $76.22. The company has a debt-to-equity ratio of 0.22, a quick ratio of 0.79 and a current ratio of 1.34. Cooper Companies has a 1 year low of $61.78 and a 1 year high of $89.83. The stock has a market capitalization of $13.61 billion, a PE ratio of 34.54, a P/E/G ratio of 1.80 and a beta of 1.02.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the business. Root Financial Partners LLC raised its position in shares of Cooper Companies by 104.5% during the 4th quarter. Root Financial Partners LLC now owns 317 shares of the medical device company’s stock worth $26,000 after acquiring an additional 162 shares in the last quarter. Bell Investment Advisors Inc boosted its holdings in Cooper Companies by 106.3% in the third quarter. Bell Investment Advisors Inc now owns 425 shares of the medical device company’s stock valued at $29,000 after purchasing an additional 219 shares in the last quarter. True Wealth Design LLC boosted its holdings in Cooper Companies by 484.8% in the fourth quarter. True Wealth Design LLC now owns 462 shares of the medical device company’s stock valued at $38,000 after purchasing an additional 383 shares in the last quarter. Cromwell Holdings LLC increased its stake in Cooper Companies by 128.8% in the fourth quarter. Cromwell Holdings LLC now owns 485 shares of the medical device company’s stock valued at $40,000 after purchasing an additional 273 shares during the last quarter. Finally, Board of the Pension Protection Fund purchased a new position in Cooper Companies in the fourth quarter valued at approximately $41,000. 24.39% of the stock is owned by institutional investors and hedge funds.

Cooper Companies News Summary

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Zacks Research raised several quarterly and full‑year EPS forecasts for Cooper (FY2026–FY2028 and multiple quarters), signaling improved analyst expectations for margin and earnings momentum — a catalyst that can support the stock over time. Zacks boosts COO estimates (MarketBeat summary)
• Neutral Sentiment: A Zacks feature highlights Cooper’s premium contact‑lens momentum and margin gains as reasons to consider adding the stock, which underpins a constructive medium‑term view but notes mixed near‑term signals. Reasons to Add Cooper Companies Stock to Your Portfolio Now
• Negative Sentiment: The same analyst coverage warns of Asia market softness and broader geopolitical risks that could blunt top‑line growth for Cooper’s international lens business — a near‑term headwind that likely contributed to today’s selling. Risks: Asia weakness & geopolitical concerns (Zacks)

Cooper Companies Company Profile

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.